TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thrombocytes and International Normalized Ratio Are no Predictors for Bleeding in Application of Central Veneous Catheters
Brief Summary: Since many of the patients in an intensive care unit suffer from disorders of hemostasis, bleeding is a main concern applying central venous catheters. Even if there are some data indicating elevated international normalized ratio may not increase the risk of bleeding no clear cut-off has been defined so far. An INR \> 1.5 is generally considered to increase the risk of bleeding. Furthermore, many authors consider platelets below 50 x 109 /l as a contra-indication to CVC cannulation, since there are some data this may increase the risk of bleeding. Therefore platelet transfusion before venous puncture is suggested. In our clinical experience INR \> 1.5 and platelets \< 50 x 109 /l do not correlate with increased risk of bleeding. The aim of this study is to demonstrate, that coagulopathy, defined by INR and platelet count, is not decisive for bleeding.


Options:
A: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3
C: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Therapeutic platelet transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic platelet transfusion | Intervention Type: BIOLOGICAL; Name: Prophylactic platelet transfusion; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Therapeutic platelet transfusion; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thrombocytes and International Normalized Ratio Are no Predictors for Bleeding in Application of Central Veneous Catheters
Brief Summary: Since many of the patients in an intensive care unit suffer from disorders of hemostasis, bleeding is a main concern applying central venous catheters. Even if there are some data indicating elevated international normalized ratio may not increase the risk of bleeding no clear cut-off has been defined so far. An INR \> 1.5 is generally considered to increase the risk of bleeding. Furthermore, many authors consider platelets below 50 x 109 /l as a contra-indication to CVC cannulation, since there are some data this may increase the risk of bleeding. Therefore platelet transfusion before venous puncture is suggested. In our clinical experience INR \> 1.5 and platelets \< 50 x 109 /l do not correlate with increased risk of bleeding. The aim of this study is to demonstrate, that coagulopathy, defined by INR and platelet count, is not decisive for bleeding.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3
B: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Therapeutic platelet transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic platelet transfusion | Intervention Type: BIOLOGICAL; Name: Prophylactic platelet transfusion; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Therapeutic platelet transfusion; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thrombocytes and International Normalized Ratio Are no Predictors for Bleeding in Application of Central Veneous Catheters
Brief Summary: Since many of the patients in an intensive care unit suffer from disorders of hemostasis, bleeding is a main concern applying central venous catheters. Even if there are some data indicating elevated international normalized ratio may not increase the risk of bleeding no clear cut-off has been defined so far. An INR \> 1.5 is generally considered to increase the risk of bleeding. Furthermore, many authors consider platelets below 50 x 109 /l as a contra-indication to CVC cannulation, since there are some data this may increase the risk of bleeding. Therefore platelet transfusion before venous puncture is suggested. In our clinical experience INR \> 1.5 and platelets \< 50 x 109 /l do not correlate with increased risk of bleeding. The aim of this study is to demonstrate, that coagulopathy, defined by INR and platelet count, is not decisive for bleeding.


Options:
A: Arm Label: Quarantined FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Methylene blue FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Arm Label: Solvent detergent FFP; Type: ACTIVE_COMPARATOR; Interventions: Other: plasma | Intervention Type: OTHER; Name: plasma; Assigned to Arm(s): Methylene blue FFP, Quarantined FFP, Solvent detergent FFP
B: Arm Label: 1:1:1 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:1 Blood Transfusion Ratio | Arm Label: 1:1:2 Blood Transfusion Ratio; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1:1:2 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:1 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:1 Blood Transfusion Ratio | Intervention Type: BIOLOGICAL; Name: 1:1:2 Blood Transfusion Ratio; Assigned to Arm(s): 1:1:2 Blood Transfusion Ratio
C: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
D: Arm Label: No FFP transfusion prior to intervention; Type: EXPERIMENTAL; Interventions: Other: omitting FFP transfusion before an intervention | Arm Label: FFP transfusion prior to intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: omitting FFP transfusion before an intervention; Assigned to Arm(s): No FFP transfusion prior to intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thrombocytes and International Normalized Ratio Are no Predictors for Bleeding in Application of Central Veneous Catheters
Brief Summary: Since many of the patients in an intensive care unit suffer from disorders of hemostasis, bleeding is a main concern applying central venous catheters. Even if there are some data indicating elevated international normalized ratio may not increase the risk of bleeding no clear cut-off has been defined so far. An INR \> 1.5 is generally considered to increase the risk of bleeding. Furthermore, many authors consider platelets below 50 x 109 /l as a contra-indication to CVC cannulation, since there are some data this may increase the risk of bleeding. Therefore platelet transfusion before venous puncture is suggested. In our clinical experience INR \> 1.5 and platelets \< 50 x 109 /l do not correlate with increased risk of bleeding. The aim of this study is to demonstrate, that coagulopathy, defined by INR and platelet count, is not decisive for bleeding.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Therapeutic platelet transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic platelet transfusion | Intervention Type: BIOLOGICAL; Name: Prophylactic platelet transfusion; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Therapeutic platelet transfusion; Assigned to Arm(s): 1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3
C: Intervention Type: PROCEDURE; Name: central venous catheter application; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family-Supported Smoking Cessation for Chronically Ill Veterans
Brief Summary: The overarching aim of the study is to evaluate in a randomized trial the impact of a family-supported intervention compared to a standard veteran-focused telephone counseling control group to promote smoking cessation among cancer and heart disease patients.


Options:
A: Arm Label: Champix plus counselling; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: counselling alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Counselling alone | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix plus counselling | Intervention Type: BEHAVIORAL; Name: Counselling alone; Assigned to Arm(s): counselling alone
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Family-supported | Arm Label: Arm 2; Type: OTHER; Interventions: Behavioral: Standard Telephone counseling | Intervention Type: BEHAVIORAL; Name: Family-supported; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Standard Telephone counseling; Assigned to Arm(s): Arm 2
C: Arm Label: Intercom; Type: EXPERIMENTAL; Interventions: Other: INTERdisciplinary COMmunity-based COPD management (INTERCOM) | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERdisciplinary COMmunity-based COPD management (INTERCOM); Assigned to Arm(s): Intercom
D: Arm Label: QualiCCare education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: active comparator, QualiCCare education | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: active comparator, QualiCCare education; Assigned to Arm(s): QualiCCare education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)
Brief Summary: Adolescent idiopathic scoliosis (AIS) is a structural curve of the spine with no clear underlying cause. Bracing is currently the standard of care for preventing curve progression and treating AIS. However, the effectiveness of bracing remains unclear. The purpose of this study is to compare the risk of curve progression in adolescents with AIS who wear a brace versus those who do not and to determine whether there are reliable factors that can predict the usefulness of bracing for a particular individual with AIS.


Options:
A: Arm Label: Schroth group; Type: EXPERIMENTAL; Interventions: Other: Schroth Exercises | Arm Label: Stabilization group; Type: EXPERIMENTAL; Interventions: Other: Core stabilization Exercises | Intervention Type: OTHER; Name: Schroth Exercises; Assigned to Arm(s): Schroth group | Intervention Type: OTHER; Name: Core stabilization Exercises; Assigned to Arm(s): Stabilization group
B: Arm Label: Brace; Type: ACTIVE_COMPARATOR; Interventions: Device: Brace | Arm Label: Observation; Type: ACTIVE_COMPARATOR; Interventions: Other: Observation | Intervention Type: DEVICE; Name: Brace; Assigned to Arm(s): Brace | Intervention Type: OTHER; Name: Observation; Assigned to Arm(s): Observation
C: Arm Label: Schroth exercises; Type: EXPERIMENTAL; Interventions: Other: The Schroth exercises treatment | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Global Postural Re-education (Montréal); Type: ACTIVE_COMPARATOR; Interventions: Other: Global Postural Re-Education | Intervention Type: OTHER; Name: The Schroth exercises treatment; Assigned to Arm(s): Schroth exercises | Intervention Type: OTHER; Name: Global Postural Re-Education; Assigned to Arm(s): Global Postural Re-education (Montréal)
D: Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Based Traditional Scoliosis Exercise | Arm Label: Training Group; Type: EXPERIMENTAL; Interventions: Other: Home Based Traditional Scoliosis Exercise, Other: Home Based Core Stabilization Training | Intervention Type: OTHER; Name: Home Based Traditional Scoliosis Exercise; Assigned to Arm(s): Control Group, Training Group | Intervention Type: OTHER; Name: Home Based Core Stabilization Training; Assigned to Arm(s): Training Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Diabetic nephropathy is the leading cause of chronic kidney disease all the world in spite of progress in new treatment for diabetes and anti hypertensive drugs. Additional treatments are thus needed to arrest the progression of diabetic nephropathy. Although there is insufficient evidence to suggest that a low-protein diet improves renal dysfunction, it is recommended as a mainstay of nutritional management. We here assessed the role of low protein diet in renal function as well as albuminuria in type 2 diabetic patients with nephropathy for a median of 5 years.


Options:
A: Intervention Type: BEHAVIORAL; Name: low protein diet; Assigned to Arm(s): N/A
B: Arm Label: low protein diet; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: low protein diet plusα-keto acid; Type: EXPERIMENTAL; Interventions: Behavioral: low protein diet plus α-keto acid | Arm Label: very low protein diet plus α-keto acid; Type: EXPERIMENTAL; Interventions: Behavioral: very low protein diet plus α-keto acid | Intervention Type: BEHAVIORAL; Name: low protein diet plus α-keto acid; Assigned to Arm(s): low protein diet plusα-keto acid | Intervention Type: BEHAVIORAL; Name: very low protein diet plus α-keto acid; Assigned to Arm(s): very low protein diet plus α-keto acid
C: Arm Label: VLPD diet; Type: EXPERIMENTAL; Interventions: Behavioral: Very low protein diet | Arm Label: LPD diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low protein diet | Intervention Type: BEHAVIORAL; Name: Very low protein diet; Assigned to Arm(s): VLPD diet | Intervention Type: BEHAVIORAL; Name: Low protein diet; Assigned to Arm(s): LPD diet
D: Arm Label: Standard Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Arm Label: Intensive Treatment Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Behavioral: Stop smoking, Drug: Glucose lowering therapy, Drug: Blood pressure lowering therapy, Drug: Lipid lowering therapy | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: BEHAVIORAL; Name: Stop smoking; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Glucose lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Blood pressure lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm | Intervention Type: DRUG; Name: Lipid lowering therapy; Assigned to Arm(s): Intensive Treatment Arm, Standard Treatment Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Subjects With Moderate to Severe Chronic Low Back Pain
Brief Summary: The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administrated tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain of the lower back, in comparison with placebo and Oxycodone Controlled Release (CR).


Options:
A: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: tapentadol (CG5503) ER | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone CR | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tapentadol (CG5503) ER; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: oxycodone CR; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003
C: Arm Label: Tapentadol Prolonged Release; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol Prolonged Release | Intervention Type: DRUG; Name: Tapentadol Prolonged Release; Assigned to Arm(s): Tapentadol Prolonged Release
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: tapentadol (CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: tapentadol (CG5503); Assigned to Arm(s): 001

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Naturalistic, Prospective, Single Centre, Double Blinded, Fixed Dose, Randomised, Four Week Comparison Study Investigating Efficacy, Tolerability and Safety of 200 mg Per Day Versus 400 mg Per Day Quetiapine Fumarate in 200 Drug naïve First Episode Psychosis Patients Aged 15 to 25 Years.
Brief Summary: The purpose of this study is determine the minimal effective dose and the impact on:

1. treatment outcomes at 4, 12 and/or 48 weeks the treatment has required to treat patients experiencing the first psychotic episode
2. the final maintenance doses
3. the use of other medications
4. the amount of changes to other antipsychotic medication
5. the number of hospitalization days


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
C: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group
D: Intervention Type: DRUG; Name: Quetiapine Fumarate; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomised, Clinical Study to Examine the Effects of a Single Bolus Erythropoietin on Left Ventricular Function in Patients With an Acute Myocardial Infarction
Brief Summary: The primary objective of this study is to establish the effects of a single bolus of EPO, administered within three hours after a primary PCI for a first acute myocardial infarction, on left ventricular function.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin alfa | Intervention Type: DRUG; Name: epoetin alfa; Assigned to Arm(s): Epoetin alfa
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: epoetinum | Intervention Type: DRUG; Name: epoetinum; Assigned to Arm(s): 2

Answer: C